During the last session, Atea Pharmaceuticals Inc. (NASDAQ:AVIR)’s traded shares were 1.88 million. At the end of the trading day, the stock’s price was $4.63, reflecting an intraday loss of -3.74% or -$0.18. The 52-week high for the AVIR share is $9.79, that puts it down -111.45 from that peak though still a striking 36.5% gain since the share price plummeted to a 52-week low of $2.94. The company’s market capitalization is $374.66M, and the average intraday trading volume over the past 10 days was 1.6 million shares, and the average trade volume was 751.36K shares over the past three months.
Atea Pharmaceuticals Inc. (AVIR) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 2.70. AVIR has a Sell rating from 1 analyst(s) out of 4 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.47.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Atea Pharmaceuticals Inc. (NASDAQ:AVIR) trade information
Atea Pharmaceuticals Inc. (AVIR) registered a -3.74% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -3.74% in intraday trading to $4.63 this Thursday, 05/25/23, hitting a weekly high. The stock’s 5-day price performance is 28.97%, and it has moved by 39.88% in 30 days. Based on these gigs, the overall price performance for the year is -38.51%. The short interest in Atea Pharmaceuticals Inc. (NASDAQ:AVIR) is 1.94 million shares and it means that shorts have 4.33 day(s) to cover.
The consensus price target of analysts on Wall Street is $5.33, which implies an increase of 13.13% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.00 and $8.00 respectively. As a result, AVIR is trading at a discount of -72.79% off the target high and 13.61% off the low.
Atea Pharmaceuticals Inc. (AVIR) estimates and forecasts
Statistics show that Atea Pharmaceuticals Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Atea Pharmaceuticals Inc. (AVIR) shares have gone down -1.70% during the last six months, with a year-to-date growth rate less than the industry average at -43.17% against 11.40. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to shrink -23.70% this quarter and then drop -430.00% in the quarter after that.
While earnings are projected to return -201.40% in 2023.
Atea Pharmaceuticals Inc. is due to release its next quarterly earnings between August 07 and August 11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Atea Pharmaceuticals Inc. (NASDAQ:AVIR)’s Major holders
Atea Pharmaceuticals Inc. insiders own 9.10% of total outstanding shares while institutional holders control 70.68%, with the float percentage being 77.75%. FMR, LLC is the largest shareholder of the company, while 190 institutions own stock in it. As of Mar 30, 2023, the company held over 11.57 million shares (or 13.88% of all shares), a total value of $38.77 million in shares.
The next largest institutional holding, with 8.04 million shares, is of Blackrock Inc.’s that is approximately 9.64% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $26.94 million.
Also, the Mutual Funds coming in first place with the largest holdings of Atea Pharmaceuticals Inc. (AVIR) shares are Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund. Data provided on Feb 27, 2023 indicates that Fidelity Growth Company Fund owns about 2.96 million shares. This amounts to just over 3.55 percent of the company’s overall shares, with a $10.48 million market value. The same data shows that the other fund manager holds slightly less at 2.25 million, or about 2.70% of the stock, which is worth about $10.84 million.